RxDoctor Payments Data

Grant Bullock

Psychiatry · Las Vegas, NVNPI 1174086391

Payments from drug & device makers

$1,514in general payments, 2019–2025

Across 29 payments — averaging $52.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$719
  • Neurocrine Biosciences, Inc.$294
  • Otsuka America Pharmaceutical, Inc.$157
  • Vanda Pharmaceuticals Inc.$117
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$71
  • Lundbeck LLC$70
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$1,514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,514 in reported general payments places this provider in the 70th percentile of 243 psychiatry providers in Nevada.

See all psychiatry providers in Nevada

Medicare billing

Part B allowed, 2024
$73,341
Medicare patients
61
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl62$77,217
Hydroxyzine Hcl84$1,632
Clonazepam101$1,078
Sertraline Hcl31$902
Quetiapine Fumarate ErQuetiapine Fumarate16$781
Duloxetine Hcl52$761
Aripiprazole42$516
Buspirone Hcl26$418
Mirtazapine62$412
Paroxetine Hcl25$396
Trazodone Hcl59$375
Prazosin Hcl24$310
Bupropion XlBupropion Hcl22$282
Escitalopram Oxalate32$263
Quetiapine Fumarate19$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$31$77,21762 claims
Almatica Pharma LLCSertraline Hcl$23$90231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 243 psychiatry providers in Nevada.

Other psychiatry in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →